即使是CD20低表达的B细胞系也能被IGM-2323有效清除。 此外,与双特异性IgG相比,IGM-2323对CD20表达水平显著降低的利妥昔单抗耐药细胞系的杀灭作用更强,且效应靶比更低。与双特异性IgG中观察到的显著细胞因子释放相反,IGM-2323细胞毒作...
today announced that it expects the first clinical data from its Phase 1 trial evaluating IGM-2323 will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will...